CIPLA \u2014 Recent Activity

Fennec Pharmaceuticals Inc (FENC) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ...

Fennec Pharmaceuticals Inc (FENC) reports a 75% increase in Q4 net product sales, debt-free status, and strategic market expansions amid rising expenses.

Click to open →

B Riley Reaffirms Fennec's Buy Rating, US$16.00 Price Target After Cipla Settlement

B. Riley reiterated its buy rating on the shares of Fennec Pharmaceuticals (FRX.TO, FENC) and its US

Click to open →

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State

Click to open →

India's Gland Pharma posts higher quarterly profit on strong US, Europe demand

Jan 28 () - India's Gland Pharma reported a nearly 28% jump in third-quarter profit on Wednesday, boosted by strong ​sales in the key European and U. The Hyderabad-based company ‌reported a consolidated net profit of 2.

Click to open →

Cipla Ltd (BOM:500087) Q3 2026 Earnings Call Highlights: Strategic Growth Amidst Margin Challenges

Cipla Ltd (BOM:500087) reports robust growth in key segments despite facing margin pressures and supply disruptions.

Click to open →

India's Cipla posts steeper-than-expected quarterly profit slump on tumour drug supply crunch

Jan 23 (Reuters) - Cipla, India's third-largest drugmaker by revenue, reported a steeper-than-expected 57% fall in quarterly profit on Friday, dragged down by a production halt at one of its exclusive

Click to open →

India's Lupin posts surge in quarterly profit on strong respiratory drugs demand

(Reuters) -Indian drugmaker Lupin posted a 73.3% jump in second-quarter profit on Thursday, driven by strong demand for its respiratory drugs.

Click to open →

India's Alembic Pharma posts quarterly profit jump on strong generics demand

(Reuters) -Indian drugmaker Alembic Pharmaceuticals posted a 20.4% rise in second-quarter profit on Tuesday, aided by strong demand for its generic drugs as well as new launches in its key U.S. market

Click to open →

India's Gland Pharma posts higher quarterly profit on Cenexi boost

(Reuters) -India's Gland Pharma reported a 12% rise in second-quarter profit on Monday, as recovery at its European unit Cenexi bolstered margins.

Click to open →

Indian drugmaker Cipla's global CEO Umang Vohra to step down, COO to take over

By Rishika Sadam and Kashish Tandon (Reuters) -Cipla's global chief executive and managing director, Umang Vohra, will step down at the end of March after almost a decade in the top role, the Indian

Click to open →